Candidate gene microarray analysis in peripheral blood cells for studying hypertension/obesity

Personalized Medicine

Volumn 6, Issue 3, 2009, Pages 269-291

  Marteau, Jean Brice ^a   Samara, Anastasia ^a   Dedoussis, Georges ^b   Pfister, Michèle ^a   Visvikis Siest, Sophie ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Cardiovascular; Gene expression; Hypertension; Leukocyte; Obesity

Indexed keywords

ADRENERGIC RECEPTOR; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; ARACHIDONIC ACID; CD14 ANTIGEN; CELL ADHESION MOLECULE; CYCLIC AMP; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EOTAXIN; EPITHELIAL SODIUM CHANNEL; FATTY ACID BINDING PROTEIN 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; PROTEIN ADRA2A; PROTEIN ALOX5; PROTEIN CHRM1; PROTEIN SCNN1B; PROTEIN SELE; PROTEIN SELL; PROTEIN SELP; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NR1H4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE NUMBER; GENE TARGETING; GENETIC VARIABILITY; HOUSEKEEPING GENE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; UNINDEXED SEQUENCE; UPREGULATION;

EID: 67651156195     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.6     Document Type: Article

References (42)

1. Krauss RM, Winston M: Obesity: impact on cardiovascular disease. Circulation 98, 1472-1476 (1998).
2. Bouloumié A, Casteilla L, Lafontan M: Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first? Arterioscler. Thromb. Vasc. Biol. 28(7), 1211-1213 (2008).
3. Abramson JL, Lewisr C, Murrah NV, Anderson GT, Vaccarino V: Relation of C-reactive protein and tumor necrosis factor-α to ambulatory blood pressure variability in healthy adults. Am. J. Cardiol. 98(5), 649-652 (2006).
4. Ma J, Dempsey AA, Stamatiou D, Marshall KW, Liew CC: Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis 191(1), 63-72 (2007).
5. Crujeiras AB, Parra D, Milagro FI et al.: Differential expression of oxidative stress and inflammation related genes in peripheral blood mononuclear cells in response to a low-calorie diet: a nutrigenomics study. OMICS 12(4), 251-261 (2008).
6. De Mello VD, Kolehmainen M, Schwab U et al.: Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism 57(2), 192-199 (2008).
7. De Mello VD, Kolehmainen M, Pulkkinen L et al.: Downregulation of genes involved in NFκB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study. Diabetologia 51(11), 2060-2067 (2008).
8. O'Rourke RW, Kay T, Lyle EA et al.: Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin. Exp. Immunol. 164(1), 39-46 (2006).
9. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P: Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 10(12), 1564-1571 (2004).
10. Bull TM, Coldren CD, Moore M et al.: Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 170(8), 827-828 (2004).
11. Visvikis-Siest S, Siest G: The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clin. Chem. Lab. Med. 46(6), 733-747 (2008).
12. Visvikis-Siest S, Marteau JB, Samara A, Berrahmoune H, Marie B, Pfister M: Peripheral blood mononuclear cells (PBMCs): a possible model for studying cardiovascular biology systems. Clin. Chem. Lab. Med. 45(9), 1154-1168 (2007).
13. Marteau JB, Mohr S, Pfister M, Visvikis-Siest S: Collection and storage of human blood cells for mRNA expression profiling: a 15-month stability study. Clin. Chem. 51(7), 1250-1252 (2005).
14. Gros R, Benovic JL, Tan M, Feldman RD: G-protein-coupled receptor kinase activity is increased in hypertension. J. Clin. Invest. 99(9), 2087-2093 (1997).
15. Heximer SP, Knutsen RH, Sun X et al.: Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J. Clin. Invest. 111(4), 445-452 (2003).
16. Tang KM, Wang GR, Lu P et al.: Regulator of G-Protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat. Med. 9(12), 1506-1512 (2003).
17. Yang J, Kamide K, Kokubo Y et al.: Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. J. Hypertens. 23(8), 1497-1505 (2005).
18. Pratt PF, Rosolowsky M, Campbell WB: Effects of epoxyeicosatrienoic acids on polymorphonuclear leukocyte function. Life Sci. 70(21), 2521-2533 (2002).
19. Bauersachs J, Bouloumié A, Fraccafollo D et al.: Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100(3), 292-298 (1999).
20. Lehrer RI, Ganz T: Defensins of vertebrate animals. Curr. Opin. Immunol. 14(1), 96-102 (2002).
21. Yang D, Chen Q Chertov O, Oppenheim JJ: Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68(1), 9-14 (2000).
22. Koczulla R, von Degenfeld G, Kupatt C et al.: An angiogenic-role for the human peptide antibiotic LL-37/hCAP-48. J. Clin. Invest. 111(11), 1665-1672 (2003).
23. Ohara T, Morishita T, Suzuki H, Masaoka T, Nishizawa T, Hibi T: Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular market of gastric mucosal inflammation. Hepatogastroenterology 52(65), 1320-1324 (2005).
24. Barnathan ES, Raghunath PN, Tomaszewski JE, Ganz T, Cines DB, Higazi A al-R: Immunohistochemical localization of defensin in human coronary vessels. Am. J. Pathol. 150(3), 1009-1020 (1997).
25. Kougias P, Chai H, Lin PH, Qizhi Y, Lumsden AB, Chen C: Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J. Cell. Mol. Med. 9(1), 3-10 (2005).
26. Savoia C, Schiffrin EL: Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens. 15(2), 152-158 (2006).
27. Mowri HO, Patsch JR, Gotto AM Jr, Patsch W: Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. Arterioscler. Thromb. Vasc. Biol. 16(6), 755-762 (1996).
28. Deeb SS, Takata K, Peng RL, Kajiyama G, Albers JJ: A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am. J. Hum. Genet. 46(4), 822-827 (1990).
29. Vajo Z, Terry JG, Brinton EA: Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis 160(2), 495-501 (2002).
30. Ordovas JM, Tai ES: Why study gene-environment interactions? Curr. Opin. Lipidol. 19(2), 158-167 (2008).
31. Mehrabian M, Allayee H, Stockton J et al.: Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat. Genet. 37(11), 1224-1233 (2005).
32. Kaaman M, Ryden M, Axelsson T et al.: ALOX5AP expression, but not gene haplotypes is associated with obesity and insulin resistance. Int. J. Obes. (Lond.) 30(3), 447-452 (2006).
33. Albertini JP, Valensi P, Lormeau-B, Vaysse J, Attali JR, Gattegno, L: Soluble L-selectin level is a marker for coronary artery disease in Type 2 diabetic patients. Diabetes Care 22(12), 2044-2048 (1999).
34. Morello F, de Boer RA, Steffensen KR et al.: Liver X receptors α and β regulate renin expression in vivo. J. Clin. Invest. 115(7), 1913-1922 (2005).
35. Bell CG, Benzinou M, Siddiq A et al.: Genome-wide linkage analysis for severe obesity in french caucasians finds significant susceptibility locus on chromosome 19q. Diabetes 53(7), 1857-1865 (2004).
36. Swift PA, MacGregor GA: The epithelial sodium-channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. Am. J. Pharmacogenomics 4(3), 161-168 (2004).
37. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972-978 (2007).
38. Marteau JB, Gambier N, Jeannesson E, Siest G, Visvikis-Siest S: Pharmacogenomics and-antihypertensive drugs: a path toward personalized medicine. Per. Med. 4(4), 393-412 (2007)
39. Phillips MI, Kimura B: Gene therapy for hypertension: antisense inhibition of the renin-angiotensin system. Methods Mol. Med. 108, 363-379 (2005).
40. Vanccková I, Kopkan L, Husková Z et al.: ATI receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats. Vascul. Pharmacol. 47(1), 63-67 (2007).
41. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP: Aritisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin. Investig. Drugs 17(7), 969-972 (2008).
42. Visser ME, Jakulj L, Kastelein JJ, Stroes ES: LDL-C-lowering therapy: current and future therapeutic targets. Curr. Cardiol. Rep. 10(6), 512-520 (2008).